TV Host Promotes Bronchiectasis Awareness
Insmed Inc has partnered with TV host Ty Pennington to launch "Suspect Bronchiectasis (Suspect BE)," an educational initiative aimed at increasing awareness and proper diagnosis of bronchiectasis.
Insmed Inc has partnered with TV host Ty Pennington to launch "Suspect Bronchiectasis (Suspect BE)," an educational initiative aimed at increasing awareness and proper diagnosis of bronchiectasis.
Insmed Inc has partnered with TV host Ty Pennington to launch “Suspect Bronchiectasis (Suspect BE),” an educational initiative aimed at increasing awareness and proper diagnosis of bronchiectasis.
Read MoreThe ENCORE study showed that adding an inhaled amikacin suspension to multidrug therapy improved respiratory symptoms and increased culture conversion rates.
Read MoreInsmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
Read MoreBrinsupri (brensocatib) is now the first and only authorized treatment for non-cystic fibrosis bronchiectasis in the EU for patients 12 and older with recurrent exacerbations.
Read MoreThe phase 3 ASPEN trial revealed brensocatib 10 mg and 25 mg significantly reduced bronchiectasis exacerbations, prolonged time to first exacerbation, and improved quality-of-life scores.
Read MoreInsmed’s Brinsupri (brensocatib) has been approved by the FDA as an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
Read More